Abubakar Aminu Kende, Kaneda Yudai, Ozaki Akihiko, Saito Hiroaki, Murakami Michio, Hori Daisuke, Gonda Kenji, Tsubokura Masaharu, Tabuchi Takahiro
Graduate School of Public Health, St. Luke's International University, Tokyo 104-004, Japan.
Hokkaido University School of Medicine, Hokkaido 060-8638, Japan.
Cancers (Basel). 2024 May 5;16(9):1783. doi: 10.3390/cancers16091783.
There is limited information on whether the COVID-19 pandemic was associated with decreased breast cancer screening uptake and if COVID-19 vaccination was associated with an increase in screening uptake. Our study explored the uptake of breast cancer screening in Japan after the COVID-19 pandemic and assessed its association with the COVID-19 vaccination. We analyzed data from the Japan COVID-19 and Society Internet Survey (JACSIS), a web-based prospective cohort survey, and we included 6110 women without cancer history who were aged 40 to 74 years that participated in the 2012 and 2022 surveys. We examined the regular breast cancer screening uptake before and after the pandemic and employed a multivariable Poisson regression model to seek any association between COVID-19 vaccination and screening uptake. Of 6110, 38.2% regularly participated in screening before the pandemic and 46.9% did so after the pandemic. Individuals unvaccinated due to health reasons (incidence rate ratio (IRR) = 0.47, 95% CI: 0.29-0.77, = 0.003) and for other reasons (IRR = 0.73, 95% CI: 0.62-0.86, < 0.001) were less likely to undergo screening compared to fully vaccinated individuals. There was no long-term decrease in breast cancer screening uptake after the pandemic in Japan. Vaccination was linked to increased uptake, but there was no dose relationship.
关于2019冠状病毒病大流行是否与乳腺癌筛查率下降相关，以及2019冠状病毒病疫苗接种是否与筛查率上升相关，目前信息有限。我们的研究探讨了2019冠状病毒病大流行后日本乳腺癌筛查的接受情况，并评估了其与2019冠状病毒病疫苗接种的关联。我们分析了日本2019冠状病毒病与社会互联网调查（JACSIS）的数据，这是一项基于网络的前瞻性队列调查，我们纳入了6110名年龄在40至74岁之间、无癌症病史且参加了2012年和2022年调查的女性。我们检查了大流行前后的常规乳腺癌筛查接受情况，并采用多变量泊松回归模型来寻找2019冠状病毒病疫苗接种与筛查接受情况之间的任何关联。在6110名女性中，38.2%在大流行前定期参加筛查，大流行后这一比例为46.9%。因健康原因未接种疫苗的个体（发病率比（IRR）=0.47，95%置信区间：0.29-0.77， =0.003）和因其他原因未接种疫苗的个体（IRR =0.73，95%置信区间：0.62-0.86， <0.001）与完全接种疫苗的个体相比，接受筛查的可能性较小。日本大流行后乳腺癌筛查接受率没有长期下降。疫苗接种与接受率上升有关，但没有剂量关系。
